Andreas

“What we showed in the trial was actually a 31% significant reduction in the primary endpoint at one year.” Shockwave CMO Dr. Nick West had a chance to talk with BALI Trial principal investigator Prof. Niels Thue Olsen at our #EuroPCR booth after his late-breaker this week. Hear them discuss the rationale and salient findings of the BALI trial. US Rx only. ISI bit.ly/3iEq7fC #ShockwaveIVL